ULBP2 and glioblastoma: Significantly, temozolomide (TMZ), which is used in the standard therapy for GBM, has also been proven to induce the expression of NKG2D (ULBP2) ligands on the surface of GBM cells, sensitizing them to Tγδ lymphocyte killing via both NKG2D and TCR [396].